Acalabrutinib, a second-generation bruton tyrosine kinase (Btk) inhibitor, in previously untreated chronic lymphocytic leukemia (CLL).

被引：11
|
作者：
Byrd, John C.
Jones, Jeffrey Alan
Furman, Richard R.
Stephens, Deborah Marie
Devereux, Steve
Brown, Jennifer R.
Hillmen, Peter
Hamdy, Ahmed M.
Fardis, Maria
Tawashi, Manal
Wang, Min Hui
Patel, Priti
Mittag, Diana
Krantz, Fanny
Rothbaum, Wayne
Izumi, Raquel
O'Brien, Susan Mary
Wierda, William G.
机构：
[1] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[2] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] NHS Fdn Trust Denmark Hill, Coll Hosp, London, England
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] St James Univ Hosp, Leeds, W Yorkshire, England
[7] Acerta Pharma, Santa Cruz, CA USA
[8] Pharmacycl Inc, Sunnyvale, CA USA
[9] Acerta Pharma, Redwood City, CA USA
[10] Acerta Pharma, San Carlos, CA USA
[11] Univ Calif Irvine, Irvine, CA USA
[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.7521
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7521
引用
收藏
页数：2
相关论文
共 50 条
  • [31] ACP-196: a novel covalent Bruton's tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients
    Covey, Todd
    Barf, Tjeerd
    Gulrajani, Michael
    Krantz, Fanny
    van Lith, Bart
    Bibikova, Elena
    van de Kar, Bas
    de Zwart, Edwin
    Hamdy, Ahmed
    Izumi, Raquel
    Kaptein, Allard
    CANCER RESEARCH, 2015, 75
  • [32] Variable Bruton Tyrosine Kinase (BTK) Resynthesis across Patients with Chronic Lymphocytic Leukemia (CLL) on Acalabrutinib Therapy Affect Target Occupancy and Reactivation of B-Cell Receptor (BCR) Signaling
    Alsadhan, Anfal A.
    Cheung, Jean
    Gulrajani, Michael
    Cook, Erika M.
    Pittaluga, Stefania
    Davies-Hill, Theresa
    Izumi, Raquel
    Sun, Clare C.
    Covey, Todd
    Wiestner, Adrian
    Herman, Sarah E. M.
    BLOOD, 2018, 132
  • [33] Second-Generation Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Tefferi, Ayalew
    CANCER, 2011, 117 (02) : 234 - 237
  • [34] Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia
    Li, Pei-Pei
    Lu, Kang
    Geng, Ling-Yun
    Zhou, Xiang-Xiang
    Li, Xin-Yu
    Wang, Xin
    MOLECULAR MEDICINE REPORTS, 2016, 13 (06) : 4934 - 4938
  • [35] Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor
    Alkharabsheh, Omar
    Alsayed, Alhareth
    Morlote, Diana M.
    Mehta, Amitkumar
    CURRENT ONCOLOGY, 2021, 28 (01) : 837 - 841
  • [36] The Bruton Tyrosine Kinase (BTK) Inhibitor ACP-196 Demonstrates Clinical Activity in Two Mouse Models of Chronic Lymphocytic Leukemia
    Herman, Sarah E. M.
    Montraveta, Arnau
    Niemann, Carsten U.
    Mora-Jensen, Helena
    Gulrajani, Michael
    Krantz, Fanny
    Harrington, Bonnie K.
    Covey, Todd
    Lannutti, Brian J.
    Izumi, Raquel
    Ulrich, Roger G.
    Byrd, John C.
    Wiestner, Adrian
    Johnson, Amy J.
    Woyach, Jennifer A.
    BLOOD, 2015, 126 (23)
  • [37] ACP-196 Is a Second Generation Inhibitor of Bruton Tyrosine Kinase (BTK) with Enhanced Target Specificity
    Harrington, Bonnie K.
    Gulrajani, Michael
    Covey, Todd
    Kaptein, Allard
    Van Lith, Bart
    Izumi, Raquel
    Hamdy, Ahmed
    Ulrich, Roger Glenn
    Byrd, John C.
    Lannutti, Brian J.
    Johnson, Amy J.
    BLOOD, 2015, 126 (23)
  • [38] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Brown, J. R.
    Harb, W. A.
    Hill, B. T.
    Gabrilove, J.
    Sharman, J. P.
    Schreeder, M. T.
    Barr, P. M.
    Foran, J. M.
    Miller, T. P.
    Burger, J. A.
    Kelly, K. R.
    Mahadevan, D.
    Ma, S.
    Barnett, E.
    Marine, J.
    Nava-Parada, P.
    Azaryan, A.
    Mei, J.
    Kipps, T. J.
    HAEMATOLOGICA, 2014, 99 : 54 - 55
  • [39] Efficacy and safety of first- versus second-generation Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis
    Ke, Liyuan
    Li, Su
    Huang, Danxue
    Wang, Yan
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [40] Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia
    Wong, Richard L.
    Choi, Michael Y.
    Wang, Huan-You
    Kipps, Thomas J.
    LEUKEMIA, 2024, 38 (08) : 1818 - 1821
12345